Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARV-393 in Advanced Non-Hodgkin's Lymphoma
NCT06393738Phase 1Recruiting
- Sponsor
- Arvinas
- Start
- Sep 2024
- Primary completion
- Mar 2028
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 5
01
Overview
Phase 1, open-label trial of zaloblideg in non-Hodgkin lymphoma (NHL), angioimmunoblastic T-cell lymphoma (AITL) and diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by Arvinas. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days, Percentage of Participants With Adverse Events at 40 days and 2 more. Started Sep 2024; status: recruiting.
02
Drugs
zaloblideg
03
Conditions
non-Hodgkin lymphoma (NHL)angioimmunoblastic T-cell lymphoma (AITL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06393738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06393738.